

# Most top 25 Medicare Part D Drugs had price increases above inflation in 2020

Express Scripts  
By EVERNORTH

BRAND	IN 2020	2019-2020	CHANGE IN AVERAGE SPENDING PER DOSAGE UNIT (2019-2020)	PRICE CHANGE GREATER THAN INFLATION (1%)?
Eliquis	\$7.90		5.94%	Yes
Revlimid	\$794.33		6.54%	Yes
Xarelto	\$15.45		4.07%	Yes
Januvia	\$15.81		5.28%	Yes
Trulicity	\$400.68		5.04%	Yes
Imbruvica	\$392.66		8.05%	Yes
<b>Lantus Solostar</b>	\$28.40		0.28%	No
Jardiance	\$17.44		6.33%	Yes
Humira(Cf) Pen	\$2,832.13		7.43%	Yes
Ibrance	\$613.20		5.01%	Yes
Symbicort	\$35.18		4.49%	Yes
Xtandi	\$101.49		3.76%	Yes
Novolog Flexpen	\$37.96		1.21%	Yes
Biktarvy	\$111.16		6.40%	Yes
Myrbetriq	\$13.63		5.40%	Yes
<b>Levemir Flextouch</b>	\$31.33		0.67%	No
Victoza 3-Pak	\$107.77		5.18%	Yes
Breo Ellipta	\$6.13		3.11%	Yes
Trelegy Ellipta	\$9.72		5.14%	Yes
Ozempic	\$433.67		2.68%	Yes
Pomalyst	\$906.46		6.55%	Yes
Restasis	\$9.82		5.00%	Yes
Invega Sustenna	\$1,930.37		5.19%	Yes
Enbrel Sureclick	\$1,392.91		5.13%	Yes
Latuda	\$47.06		5.37%	Yes

Note: Includes the top 25 drug products listed in the CMS Medicare drug spending dataset for Part D based on total gross spending in 2020. Prices are based on average spending per dosage unit and do not account for rebates. 2019-2020 price changes compared to the increase in the CPI-U between July 2019-July 2020. Source: KFF analysis of CMS Medicare Part D Drug Spending Dataset and Bureau of Labor Statistics data.